Regulus Therapeutics Inc. (RGLS)
Largest Insider Buys in Sector
RGLS Stock Price History Chart
RGLS Stock Performance
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a …
Insider Activity of Regulus Therapeutics Inc.
Over the last 12 months, insiders at Regulus Therapeutics Inc. have bought $7,280 and sold $30,379 worth of Regulus Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Regulus Therapeutics Inc. have bought $9.14M and sold $24,107 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Collier Kathryn J (director) — $7,280.
The last purchase of 4,000 shares for transaction amount of $7,280 was made by Collier Kathryn J (director) on 2024‑07‑25.
List of Insider Buy and Sell Transactions, Regulus Therapeutics Inc.
| 2024-07-25 | director | 4,000 0.0063% | $1.82 | $7,280 | -10.23% | |||
| 2024-01-18 | Sale | Chief Executive Officer | 14,580 0.0687% | $1.19 | $17,359 | +36.00% | ||
| 2024-01-18 | Sale | Sr. VP & General Counsel | 5,468 0.0258% | $1.19 | $6,510 | +36.00% | ||
| 2024-01-18 | Sale | Chief Financial Officer | 5,468 0.0258% | $1.19 | $6,510 | +36.00% | ||
| 2022-03-01 | Chief Scientific Officer | 76,686 0.0537% | $0.23 | $17,638 | -25.22% | |||
| 2022-02-04 | Chief Scientific Officer | 23,314 0.0156% | $0.23 | $5,362 | -25.63% | |||
| 2022-01-26 | President and CEO | 100,000 0.0685% | $0.22 | $21,520 | -15.91% | |||
| 2021-05-17 | Sale | President and CEO | 4,186 0.0053% | $0.89 | $3,726 | -53.85% | ||
| 2021-05-17 | Sale | Sr. VP & General Counsel | 860 0.0011% | $0.89 | $765 | -53.85% | ||
| 2021-02-16 | Sale | President and CEO | 4,144 0.0052% | $1.72 | $7,128 | -62.37% | ||
| 2021-02-16 | Sale | Sr. VP & General Counsel | 828 0.001% | $1.72 | $1,424 | -62.37% | ||
| 2020-12-04 | 10 percent owner | 4.4M 7.578% | $0.62 | $2.74M | +22.37% | |||
| 2020-12-04 | 10 percent owner | 4.4M 7.578% | $0.62 | $2.74M | +22.37% | |||
| 2020-12-04 | 10 percent owner | 4.4M 7.578% | $0.62 | $2.74M | +22.37% | |||
| 2020-12-04 | 10 percent owner | 4.4M 7.578% | $0.62 | $2.74M | +22.37% | |||
| 2020-12-04 | 10 percent owner | 4.4M 7.578% | $0.62 | $2.74M | +22.37% | |||
| 2020-12-04 | 10 percent owner | 4.4M 7.578% | $0.62 | $2.74M | +22.37% | |||
| 2020-12-04 | 10 percent owner | 4.4M 7.578% | $0.62 | $2.74M | +22.37% | |||
| 2020-12-04 | 10 percent owner | 4.4M 7.578% | $0.62 | $2.74M | +22.37% | |||
| 2020-12-04 | 10 percent owner | 4.4M 7.578% | $0.62 | $2.74M | +22.37% |
Insider Historical Profitability
| Hagan Joseph P | Chief Executive Officer | 57112 0.0872% | $1.51 | 4 | 14 | <0.0001% |
| Collier Kathryn J | director | 6740 0.0103% | $1.51 | 2 | 0 | <0.0001% |
| CROOKE STANLEY T | 7049500 10.7682% | $1.51 | 1 | 0 | ||
| PARSHALL B LYNNE | 7049500 10.7682% | $1.51 | 1 | 0 | ||
| MAKOWER JOSHUA | 10 percent owner | 6451056 9.8541% | $1.51 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Federated Hermes | $34.43M | 19.63 | 12.85M | +231.63% | +$24.05M | 0.08 | |
| Nea Management Company Llc | $18.63M | 9.88 | 6.47M | +232.44% | +$13.02M | 0.09 | |
| RA Capital Management, L.P. | $18M | 9.55 | 6.25M | New | +$18M | 0.02 | |
| Vivo Capital | $14.4M | 7.64 | 5M | New | +$14.4M | 1.25 | |
| Adage Capital Partners Gp L L C | $10.6M | 5.62 | 3.68M | New | +$10.6M | 0.02 |